Literature DB >> 11811878

Immunogenicity and reactogenicity of the adult tetanus-diphtheria vaccine. How many doses are necessary?

J M Bayas1, A Vilella, M J Bertran, J Vidal, J Batalla, M A Asenjo, L L Salleras.   

Abstract

The immunogenicity and reactogenicity of the tetanus-diphtheria adult type vaccine was compared in two groups: group I (n = 201, 18-30 years old, presumably vaccinated with the DTP vaccine) and group II (n = 147, > or = 45 years old, without vaccination antecedents). Before vaccination, the seroprotection levels for tetanus were 90.5% (group I) and 30.6% (group II). These rose to 99.5% and 81.7%, respectively, after administration of one vaccine dose. For diphtheria, prevaccination seroprotection levels were 38.3% (group I) and 19.0% (group II). These rose to 85.8% and 65.7%, respectively, after vaccination. The logistic regression analysis showed an association between antibody titre and age. In group II, 3 doses of Td vaccine were needed to reach titres similar to those achieved in group I with a single dose. Stated reactogenicity was greater in: young subjects, women, those with higher titres of tetanus antibodies and those receiving other vaccines simultaneously. These results confirm the need for vaccination schedules adapted to the characteristics of each population age-group.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11811878      PMCID: PMC2869770          DOI: 10.1017/s095026880100629x

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  16 in total

1.  Immunogenicity of gonococcal transferrin binding proteins during natural infections.

Authors:  Gregory A Price; Marcia M Hobbs; Cynthia Nau Cornelissen
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

Review 2.  Sex and Gender Impact Immune Responses to Vaccines Among the Elderly.

Authors:  Ashley L Fink; Sabra L Klein
Journal:  Physiology (Bethesda)       Date:  2015-11

3.  The seroepidemiology of tetanus in Catalonia, Spain.

Authors:  A Domínguez; P Plans; J Costa; J Espuñes; N Cardeñosa; L Salleras; A Plasència
Journal:  Med Microbiol Immunol       Date:  2007-01-23       Impact factor: 3.402

4.  Backward bifurcations and multiple equilibria in epidemic models with structured immunity.

Authors:  Timothy C Reluga; Jan Medlock; Alan S Perelson
Journal:  J Theor Biol       Date:  2008-01-26       Impact factor: 2.691

Review 5.  Factors That Influence the Immune Response to Vaccination.

Authors:  Petra Zimmermann; Nigel Curtis
Journal:  Clin Microbiol Rev       Date:  2019-03-13       Impact factor: 26.132

Review 6.  Adult vaccination against tetanus and diphtheria: the European perspective.

Authors:  B Weinberger
Journal:  Clin Exp Immunol       Date:  2016-07-12       Impact factor: 4.330

7.  A randomized controlled trial [corrected] administration of tetanus toxoid (TT) versus tetanus and reduced diphtheria (Td) in pregnant women.

Authors:  Maha M Salama; Osama A W Hady; Wael Ashour; Amal Mostafa; Sahar El Alkamy; Nehad El Sayed; Remon Abu El Yazeed
Journal:  J Clin Immunol       Date:  2009-04-14       Impact factor: 8.317

8.  Tetanus vaccination, antibody persistence and decennial booster: a serosurvey of university students and at-risk workers.

Authors:  M Borella-Venturini; C Frasson; F Paluan; D DE Nuzzo; G DI Masi; M Giraldo; F Chiara; A Trevisan
Journal:  Epidemiol Infect       Date:  2017-03-15       Impact factor: 4.434

9.  Recall responses to tetanus and diphtheria vaccination are frequently insufficient in elderly persons.

Authors:  Birgit Weinberger; Michael Schirmer; Raffaella Matteucci Gothe; Uwe Siebert; Dietmar Fuchs; Beatrix Grubeck-Loebenstein
Journal:  PLoS One       Date:  2013-12-11       Impact factor: 3.240

10.  Seasonal modulation of antibody response to diphtheria-tetanus-pertussis vaccination in infants: a cohort study in rural Gambia.

Authors:  Sandra G Okala; Momodou K Darboe; Fatou Sosseh; Bakary Sonko; Tisbeh Faye-Joof; Andrew M Prentice; Sophie E Moore
Journal:  BMC Public Health       Date:  2021-07-22       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.